Advertisement

Volume 132, Issue 5

 

 

August 2, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Dexpramipexole for hypereosinophilic syndromes. See the article by Panch et al.

Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease
This plenary paper provides previously undiscovered insights into mechanisms of altered hypoxia sensing, enhanced hypoxia-inducible factor 2α, and increased erythropoietin levels in polycythemia.


Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes
This clinical study report shows that dexpramipexole reduces blood and tissue eosinophils and enables reduction or cessation of glucocorticoid therapy in patients with hypereosinophilic syndromes.


A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era
This paper presents preclinical data demonstrating effective in vivo responses in a xenograft model of chronic lymphocytic leukemia using a novel CD19/CD3 bispecific antibody, and it further suggests enhanced effectiveness in combination with ibrutinib.


Identification of key lipids critical for platelet activation by comprehensive analysis of the platelet lipidome
Using a quantitative lipidomics platform, the authors shed light on how the platelet lipidome is altered during platelet activation and how these changes may modulate platelet function.


Extracellular galectins as controllers of cytokines in hematological cancer
This comprehensive Blood Spotlight explores the galectin-cytokine regulatory axis in the context of normal leukocytes and hematologic malignancies. It also discusses how extracellular galectins regulate cytokine expression, function, and secretion.


How I treat myelofibrosis after failure of JAK inhibitors
This How I Treat article examines the landscape of treatment options for patients with myelofibrosis who fail JAK inhibitor therapy.


HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization
The investigators show that heat shock protein HSP110 stabilizes wild-type and mutant MYD88, facilitating NF-κB activation in diffuse large B-cell lymphoma.


Shear-induced integrin signaling in platelet phosphatidylserine exposure, microvesicle release, and coagulation
Normal platelet function is highly dependent on receiving and processing information via complex signaling pathways. The investigators define a shear-dependent pathway stimulating integrin outside-in signaling and facilitating platelet procoagulant properties, including membrane phosphatidylserine exposure, microvesicle release, and intravascular fibrin formation.

 

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.